Emergent to launch over-the-counter opioid overdose therapy in September
Tasos Katopodis/Getty Images News

Emergent BioSolutions (NYSE:EBS) announced Wednesday that its recently approved opioid overdose therapy, Narcan nasal spray, will be available at brick-and-mortar drugstores and online pharmacies in September for over-the-counter use.
The productâs suggested retail price is $44.99 per carton or about $22.50 per dose. In April, the contract manufacturer planned to price OTC Narcan at around $50 per carton.

Meanwhile, pharmacy retailer Walgreens Boots Alliance (WBA) announced Wednesday that the product will be available at its online and physical stores as early as September 5, with a nationwide rollout expected on September 7.

Rival CVS Health (CVS) said its customers will have the option of getting OTC Narcan delivered for additional privacy. According to Bloomberg, Rite Aid (RAD) intends to stock the product in the pain-care aisle and pharmacy counter.
Walmart (WMT) said OTC Narcan will be available at some of its stores and online as early as this weekend, NBC News reported, quoting company spokesperson Tricia Moriarty.
In March, the FDA approved the 4 mg naloxone product as the first opioid overdose therapy available for OTC use, allowing Emergent (EBS) to prepare for a commercial launch in the summer.



More on Emergent 

Emergent BioSolutions Is Clearly Risky, But The Reward Could Be Substantial
Financial Woes Darken Emergent BioSolutions' Outlook (Rating Downgrade)
Emergent BioSolutions Inc. 2023 Q2 - Results - Earnings Call Presentation

Emergent BioSolutions, Inc. (EBS) Q2 2023 Earnings Call Transcript
Benchmark cuts Emergent BioSolutions to hold as company restructures
Emergent BioSolutions to cut 400 jobs, streamline operations
Emergent BioSolutions up 8% on up to $704M Ebola contract
Seeking Alphaâs Quant Rating on Emergent Biosolutions